$
2.880
+0.22(8.271%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.880
Open
2.650
VWAP
2.76
Vol
69.03K
Mkt Cap
142.55M
Low
2.640
Amount
190.52K
EV/EBITDA(TTM)
--
Total Shares
27.29M
EV
144.93M
EV/OCF(TTM)
--
P/S(TTM)
0.97
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2029Q1
FY2029Q2
FY2029Q3
27.02M
+21.71%
--
--
28.42M
+21.86%
--
--
30.43M
+23.27%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for MDxHealth SA (MDXH) for FY2025, with the revenue forecasts being adjusted by -2.97% over the past three months. During the same period, the stock price has changed by 57.38%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.97%
In Past 3 Month
Stock Price
Go Up
up Image
+57.38%
In Past 3 Month
6 Analyst Rating
up Image
122.22% Upside
Wall Street analysts forecast MDXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXH is 6.40 USD with a low forecast of 5.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
122.22% Upside
Current: 2.880
sliders
Low
5.00
Averages
6.40
High
8.00
Craig-Hallum
NULL -> Buy
initiated
$8
2025-07-17
Reason
Craig-Hallum initiated coverage of MDxHealth with a Buy rating and $8 price target.
Craig-Hallum
William Bonello
initiated
$8
2025-07-17
Reason
As previously reported, Craig-Hallum analyst William Bonello initiated coverage of MDxHealth with a Buy rating and $8 price target. The firm notes MDxHealth has the only test to evaluate the risk of undetected cancer in men with a negative biopsy. It also has a test to determine whether men classified as having low-risk cancer actually have more aggressive cancer that needs to be treated. The first test has a $500M TAM that is less than 10% penetrated, and the second test has a $600M TAM that is just 40% penetrated. Craig-Hallum is looking for 20%-plus topline growth with EBITDA breakeven this quarter, with the potential for mid-teens margins in a couple of years. The company has beaten top-line estimates in each of the past nine quarters, and also trades at less than 2-times this year's revenue - which is a steep discount to the group.
Piper Sandler
Jason Bednar
Buy
Maintains
$8 → $6
2024-11-07
Reason
Piper Sandler lowered the firm's price target on MDxHealth to $6 from $8 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 results, including revenue of $23.3M/+21% year-over-year that beat Street's $21.5M. Supporting the above-expected results was balanced growth across the company's tissue- and liquid-based testing portfolio, and management bumped 2024 guidance for a third consecutive quarter in light of the Q3 overachievement, with 2024 revenue now expected to finish between $87M-$89M/+24-27% year-over-year, Piper adds.

Valuation Metrics

The current forward P/E ratio for MDxHealth SA (MDXH.O) is -7.14, compared to its 5-year average forward P/E of -3.35. For a more detailed relative valuation and DCF analysis to assess MDxHealth SA 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.35
Current PE
-7.14
Overvalued PE
-1.90
Undervalued PE
-4.79

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-22.71
Current EV/EBITDA
38.38
Overvalued EV/EBITDA
33.58
Undervalued EV/EBITDA
-79.01

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.15
Current PS
1.13
Overvalued PS
2.17
Undervalued PS
0.13

Financials

Annual
Quarterly

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
253.3K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

MDXH News & Events

Events Timeline

2025-08-05 (ET)
2025-08-05
16:40:19
Bio-Techne to divest Exosome Diagnostics business to Mdxhealth
select
2025-08-05
16:27:41
MDxHealth reports Q2 EPS (15c) vs. (42c) last year
select
2025-02-26 (ET)
2025-02-26
16:18:45
MDxHealth backs prior FY25 revenue guidance of $108M-110M, consensus $103.94M
select
Sign Up For More Events

News

7.0
01-13Business Insider
MDxHealth Q4 Preliminary Revenue Climbs; Initiates 2025 Revenue Outlook
7.0
01-13Yahoo Finance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
7.0
01-13NASDAQ.COM
MDxHealth Q4 Preliminary Revenue Climbs; Initiates 2025 Revenue Outlook
Sign Up For More News

FAQ

arrow icon

What is MDxHealth SA (MDXH) stock price today?

The current price of MDXH is 2.88 USD — it has increased 8.27 % in the last trading day.

arrow icon

What is MDxHealth SA (MDXH)'s business?

arrow icon

What is the price predicton of MDXH Stock?

arrow icon

What is MDxHealth SA (MDXH)'s revenue for the last quarter?

arrow icon

What is MDxHealth SA (MDXH)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for MDxHealth SA (MDXH)'s fundamentals?

arrow icon

How many employees does MDxHealth SA (MDXH). have?

arrow icon

What is MDxHealth SA (MDXH) market cap?